Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals took a tumble today and lost -€0.700 (-3.560%).
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | -3.560% | 2.704% | 1.605% | -8.702% | 7.898% | -24.643% | -35.845% |
| Viatris Inc. | -0.400% | -8.397% | -1.839% | 61.240% | 32.757% | 34.818% | 9.815% |
| Repligen Corp. | -0.780% | 9.888% | 13.019% | 48.133% | 1.384% | -9.045% | -32.800% |
| Opko Health Inc. | -0.840% | 5.357% | 3.509% | 9.158% | 8.237% | -26.953% | -62.540% |
Comments
Hikma Pharmaceuticals (HKMPF) had its "buy" rating reaffirmed by Citigroup Inc..
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat